MXPA06012989A - Microesferas de acidos nucleicos, produccion y suministro de las mismas. - Google Patents

Microesferas de acidos nucleicos, produccion y suministro de las mismas.

Info

Publication number
MXPA06012989A
MXPA06012989A MXPA06012989A MXPA06012989A MXPA06012989A MX PA06012989 A MXPA06012989 A MX PA06012989A MX PA06012989 A MXPA06012989 A MX PA06012989A MX PA06012989 A MXPA06012989 A MX PA06012989A MX PA06012989 A MXPA06012989 A MX PA06012989A
Authority
MX
Mexico
Prior art keywords
dendritic cell
diabetes
delivery
cell tolerance
treatment
Prior art date
Application number
MXPA06012989A
Other languages
English (en)
Inventor
Terrence L Scott
Jennifer Machen
Debra Lefreniere
Nick Giannoukakis
Vered Bisker-Leib
Larry L Brown
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of MXPA06012989A publication Critical patent/MXPA06012989A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Abstract

Esta solicitud se refiere a microesferas que comprenden oligonucleotidos para el tratamiento de diabetes tipo 1; estos oligonucleotidos comprenden entre aproximadamente el 30 por ciento y aproximadamente el 100 por ciento en peso de las microesferas, basandose en el peso total de las microesferas, teniendo estas microesferas un tamano de particula promedio no mayor de aproximadamente 50 micras. Los oligonucleotidos se dirigen para enlazarse con las transcripciones primarias seleccionadas a partir del grupo que consiste en las transcripciones primarias de CD4O, CD8O, y CD86, y combinaciones de las mismas.
MXPA06012989A 2004-05-12 2005-05-12 Microesferas de acidos nucleicos, produccion y suministro de las mismas. MXPA06012989A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57027304P 2004-05-12 2004-05-12
US62548304P 2004-11-05 2004-11-05
PCT/US2005/016689 WO2005112885A2 (en) 2004-05-12 2005-05-12 Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1

Publications (1)

Publication Number Publication Date
MXPA06012989A true MXPA06012989A (es) 2007-06-12

Family

ID=35134160

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06012989A MXPA06012989A (es) 2004-05-12 2005-05-12 Microesferas de acidos nucleicos, produccion y suministro de las mismas.

Country Status (11)

Country Link
US (2) US7884085B2 (es)
EP (1) EP1758558B1 (es)
JP (2) JP2007537288A (es)
CN (1) CN103432079A (es)
AU (1) AU2005244851B2 (es)
CA (1) CA2566199C (es)
DK (1) DK1758558T3 (es)
ES (1) ES2442115T3 (es)
MX (1) MXPA06012989A (es)
PT (1) PT1758558E (es)
WO (1) WO2005112885A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
CN103432079A (zh) * 2004-05-12 2013-12-11 巴克斯特国际公司 含有寡核苷酸的微球体及其在制备用于治疗1型糖尿病的药物中的应用
US7815941B2 (en) * 2004-05-12 2010-10-19 Baxter Healthcare S.A. Nucleic acid microspheres, production and delivery thereof
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
CA2604225A1 (en) * 2005-04-27 2006-11-02 Baxter International Inc. Surface-modified microparticles and methods of forming and using the same
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
EP2007435B1 (en) 2006-03-31 2019-12-18 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
AU2013213750B2 (en) * 2006-08-04 2013-09-26 Baxter Healthcare S.A. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
CN101500616A (zh) * 2006-08-04 2009-08-05 巴克斯特国际公司 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物
JP2010505882A (ja) * 2006-10-06 2010-02-25 バクスター・インターナショナル・インコーポレイテッド 表面改質微粒子を含むマイクロエンカプセルならびに、その形成および使用の方法
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
EP2144600A4 (en) 2007-04-04 2011-03-16 Massachusetts Inst Technology POLY (AMINIC ACID) TARGET MOLECULES
MX2010003642A (es) 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
PL2982753T3 (pl) * 2008-04-18 2019-03-29 Baxter International Inc. Kompozycja na bazie mikrosfer do zapobiegania i/lub cofania nowego przypadku cukrzycy autoimmunologicznej
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
AU2014348184B2 (en) 2013-11-18 2020-08-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies
US20220354888A1 (en) * 2016-08-03 2022-11-10 Aalborg Universitet ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US373337A (en) * 1887-11-15 Shaft-hanger
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
JPS523342B2 (es) * 1972-01-26 1977-01-27
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4584894A (en) * 1984-02-29 1986-04-29 Borg-Warner Corporation Transmission anti-clash and anti-rattle brake
US5417986A (en) * 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
DE3678308D1 (de) * 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
EP0248531A3 (en) 1986-05-02 1988-09-28 Southern Research Institute Encapsulated nucleic acids
ES2053549T3 (es) * 1986-08-11 1994-08-01 Innovata Biomed Ltd Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion.
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US4848542A (en) * 1988-04-18 1989-07-18 Richard Burnette Package for retaining and mounting a mirror
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
USRE38385E1 (en) * 1989-02-16 2004-01-13 Nektar Therapeutics Storage of materials
EP0471036B2 (en) * 1989-05-04 2004-06-23 Southern Research Institute Encapsulation process
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
DE69133136T2 (de) * 1990-05-16 2003-06-18 Southern Res Inst Birmingham Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums
JPH0436233A (ja) * 1990-05-29 1992-02-06 Biomaterial Universe Kk 生理活性物質含有生体内分解吸収性の徐放性製剤
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
AU1442592A (en) * 1991-02-20 1992-09-15 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5525519A (en) * 1992-01-07 1996-06-11 Middlesex Sciences, Inc. Method for isolating biomolecules from a biological sample with linear polymers
US5173454A (en) * 1992-01-09 1992-12-22 Corning Incorporated Nanocrystalline materials
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
DE4211169C1 (es) 1992-03-31 1993-06-03 Klaus Kretzschmar
JP2651320B2 (ja) * 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
EP0595030A3 (en) * 1992-10-01 1995-06-07 Tanabe Seiyaku Co Composition of microspheres with several delayed release nuclei and its preparation process.
JPH08503950A (ja) * 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
WO1994018947A1 (en) 1993-02-16 1994-09-01 Sharifa Karali High purity protamine-dna complex and use of same
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) * 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
ES2215207T3 (es) * 1993-03-09 2004-10-01 Baxter International Inc. Microparticulas de macromoleculas y metodos de produccion.
US5994314A (en) * 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
TW360548B (en) 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
EP0727984B1 (en) * 1993-11-18 2003-06-25 Sirtex Medical Limited Controlled release preparation
DK0729353T4 (da) * 1993-11-19 2012-10-01 Alkermes Inc Fremstilling af bionedbrydelige mikropartikler som indeholder et biologisk aktivt middel
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5858973A (en) 1994-02-23 1999-01-12 The General Hospital Corporation Transcription factor and uses therefor
US5972707A (en) * 1994-06-27 1999-10-26 The Johns Hopkins University Gene delivery system
PT773781E (pt) 1994-08-04 2004-03-31 Elan Drug Delivery Ltd Sistemas solidos de entrega para libertacao controlada de moleculas incorporadas nos mesmos e metodos para a sua producao
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5542920A (en) 1994-09-12 1996-08-06 Delab Needle-less parenteral introduction device
US6387399B1 (en) * 1994-12-02 2002-05-14 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microencapsulated bioactive agents and method of making
US5877021A (en) * 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6265389B1 (en) * 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
SE505146C2 (sv) * 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US6270795B1 (en) * 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US5958769A (en) * 1996-01-18 1999-09-28 Fred Hutchinson Cancer Research Center Compositions and methods for mediating cell cycle progression
GB9607035D0 (en) 1996-04-03 1996-06-05 Andaris Ltd Spray-dried microparticles as therapeutic vehicles
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US6395302B1 (en) * 1996-11-19 2002-05-28 Octoplus B.V. Method for the preparation of microspheres which contain colloidal systems
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6077833A (en) 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
ES2205481T3 (es) 1997-04-17 2004-05-01 Amgen Inc. Microparticulas biodegradables para la liberacion sostenida de farmacos terapeuticos.
US6153211A (en) * 1997-07-18 2000-11-28 Infimed, Inc. Biodegradable macromers for the controlled release of biologically active substances
WO1999008984A1 (en) * 1997-08-18 1999-02-25 Exxon Chemical Patents Inc. Process to alkylate an aromatic with a dilute stream comprising propylene and ethylene
US6042792A (en) * 1997-09-18 2000-03-28 International Flavors & Fragrances Inc. Apparatus for preparing a solid phase microparticulate composition
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) * 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
AU749625B2 (en) 1998-01-16 2002-06-27 Johns Hopkins University, The Oral delivery of nucleic acid vaccines by particulate complexes
US20040186071A1 (en) * 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US6395253B2 (en) * 1998-04-23 2002-05-28 The Regents Of The University Of Michigan Microspheres containing condensed polyanionic bioactive agents and methods for their production
US6197584B1 (en) * 1998-05-01 2001-03-06 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 expression
ATE324913T1 (de) * 1998-08-14 2006-06-15 Valentis Inc Co-lyophilisierter komplex umfassend einen nukleinsäurevektor und ein formulierungsagens
US6270802B1 (en) * 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
EP1143934B1 (en) 1999-01-13 2003-06-04 Johns Hopkins University School of Medicine Genetic immunization with co-delivery of nucleic acid and cytokines
GB9904627D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Polymer compositions for polynucleotide delivery
US6630169B1 (en) * 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
AU3957400A (en) 1999-04-16 2000-11-02 Novo Nordisk A/S Dry, mouldable drug formulation
EP1046651A1 (en) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
AU779395B2 (en) 1999-04-30 2005-01-20 Institut De Recherche Cliniques De Montreal (Ircm) Mutant human CD80 and compositions for and methods of making and using the same
WO2000066715A1 (de) 1999-05-04 2000-11-09 Genethor Gmbh Verfahren zur reduzierung von spezifischen immunreaktionen
ES2207123T3 (es) 1999-06-14 2004-05-16 Baxter International Inc. Microesferas de liberacion sostenida.
AU1186401A (en) 1999-06-23 2001-01-22 Sedum Laboratories, Inc. Ionically formulated biomolecule microcarriers
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
FR2809309B1 (fr) * 2000-05-23 2004-06-11 Mainelab Microspheres a liberation prolongee pour administration injectable
DE60127954T2 (de) 2000-05-26 2008-01-17 Symphogen A/S Rekombinante oder gereinigte polyklonale antikörper zur behandlung den allergien
US6849259B2 (en) * 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
KR100392501B1 (ko) * 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
EP1324776B2 (en) * 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
SE518007C2 (sv) * 2000-11-16 2002-08-13 Bioglan Ab Förfarande för framställning av mikropartiklar
AU2002256971B2 (en) 2000-12-28 2008-04-03 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
EP1801123A3 (en) 2000-12-28 2007-11-21 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US6896905B2 (en) * 2001-02-15 2005-05-24 Rohm And Haas Company Porous particles, their aqueous dispersions, and method of preparation
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP2005500304A (ja) 2001-06-21 2005-01-06 アルタス バイオロジックス インコーポレイテッド 球状タンパク質粒子およびそれらの作製方法および使用方法
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
US20030064033A1 (en) 2001-08-16 2003-04-03 Brown Larry R. Propellant-based microparticle formulations
GB0207440D0 (en) * 2002-03-28 2002-05-08 Ppl Therapeutics Scotland Ltd Tolerogenic antigen-presenting cells
AU2005254062B2 (en) 2002-04-11 2011-02-17 Medimmune, Llc High pressure spray-dry of bioactive materials
EP1507874A4 (en) 2002-05-28 2006-06-28 Mirus Bio Corp COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION USING POLYNUCLEOTIDES
US6900998B2 (en) * 2002-05-31 2005-05-31 Midwest Research Institute Variable-speed wind power system with improved energy capture via multilevel conversion
AU2003251592A1 (en) * 2002-06-21 2004-01-06 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
US20040014698A1 (en) 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
CN1688275B (zh) 2002-09-11 2012-05-30 田边三菱制药株式会社 微球的制备方法
WO2004058156A2 (en) 2002-12-17 2004-07-15 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
US20060002862A1 (en) * 2002-12-17 2006-01-05 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
AU2003291527A1 (en) 2002-12-31 2004-07-29 Nektar Therapeutics Antibody-containing particles and compositions
LT2335725T (lt) * 2003-04-04 2017-01-25 Genentech, Inc. Didelės koncentracijos antikūno ir baltymo kompozicijos
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
ES2216707B1 (es) 2003-04-08 2005-12-16 Josep Maria Aran Perramon Secuencia oligoribonucleotidica homologa a una region del cdna que codifica para el receptor cd40 humano y oligoribonucleotidos duplex, vectores, composiciones farmaceuticas y usos correspondientes.
PT1639011E (pt) * 2003-06-30 2009-01-20 Domantis Ltd Anticorpos (dab) de domínio único peguilados
US7066023B2 (en) 2003-07-14 2006-06-27 Environmental Security Corporation Distributed sensor array for fluid contaminant monitoring
US8075919B2 (en) 2003-07-18 2011-12-13 Baxter International Inc. Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
EP1713332A4 (en) 2004-01-23 2010-08-18 Avi Biopharma Inc ANTISENSE OLIGOMERS AND METHOD FOR INDUCTION OF IMMUNOTHERAPY AND IMMUNOSUPPRESSION
CA2555791A1 (en) * 2004-02-12 2005-08-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Highly concentrated liquid formulations of anti-egfr antibodies
US7815941B2 (en) 2004-05-12 2010-10-19 Baxter Healthcare S.A. Nucleic acid microspheres, production and delivery thereof
CN103432079A (zh) * 2004-05-12 2013-12-11 巴克斯特国际公司 含有寡核苷酸的微球体及其在制备用于治疗1型糖尿病的药物中的应用
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
WO2006072527A1 (de) 2005-01-05 2006-07-13 Siemens Aktiengesellschaft Head-up-display für ein kraftfahrzeug
JP4595112B2 (ja) 2005-02-14 2010-12-08 独立行政法人産業技術総合研究所 タンパク質の高効率分離または濃縮方法
CN101166763B (zh) 2005-04-18 2012-09-19 伊达研究和发展有限公司 稳定的抗乙肝病毒(hbv)抗体配制剂
RU2303833C2 (ru) * 2005-07-26 2007-07-27 Самсунг Электро-Меканикс Ко., Лтд. Осветительное устройство
BRPI0620316A2 (pt) * 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
CN101500616A (zh) * 2006-08-04 2009-08-05 巴克斯特国际公司 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物
US8002046B2 (en) * 2008-10-10 2011-08-23 Neeb Daniel A Apparatus for reducing the incidence of tampering with automatic fire sprinkler assemblies

Also Published As

Publication number Publication date
AU2005244851B2 (en) 2010-08-26
US7884085B2 (en) 2011-02-08
CA2566199C (en) 2013-10-22
CA2566199A1 (en) 2005-12-01
JP2011256204A (ja) 2011-12-22
EP1758558A2 (en) 2007-03-07
PT1758558E (pt) 2013-12-05
WO2005112885A2 (en) 2005-12-01
US20060024240A1 (en) 2006-02-02
EP1758558B1 (en) 2013-10-16
CN103432079A (zh) 2013-12-11
JP2007537288A (ja) 2007-12-20
JP5457414B2 (ja) 2014-04-02
ES2442115T3 (es) 2014-02-10
AU2005244851A1 (en) 2005-12-01
WO2005112885A3 (en) 2006-02-09
US20100260855A1 (en) 2010-10-14
DK1758558T3 (da) 2014-01-20
US9115357B2 (en) 2015-08-25

Similar Documents

Publication Publication Date Title
MXPA06012989A (es) Microesferas de acidos nucleicos, produccion y suministro de las mismas.
NZ591416A (en) Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
MX2009001226A (es) Composicion basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nuevo inicio.
NZ599032A (en) Modulation of huntingtin expression
WO2010017152A3 (en) Modulation of toll-like receptor 8 expression by antisense oligonucleotides
WO2011005860A3 (en) 5' phosphate mimics
SG170780A1 (en) Compositions and methods for inhibiting expression of eg5 gene
NZ630914A (en) Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
WO2006068809A3 (en) Substrate recognition by differentiable human mesenchymal stem cells
WO2010056065A3 (en) Method for preparing microspheres and microspheres produced thereby
WO2011123621A3 (en) 2' and 5' modified monomers and oligonucleotides
WO2007031319A8 (en) Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
SG171676A1 (en) Compositions and methods for inhibiting expression of the pcsk9 gene
WO2009079592A3 (en) Modulating immune system development and function through microrna mir-146
WO2008060510A3 (en) Zinc finger nuclease for targeting the human glucocorticoid receptor locus
WO2006034348A3 (en) Enhanced antisense oligonucleotides
MXPA05007651A (es) Composiciones y metodos para la inhibicion por arnsi de la molecula de adhesion intercelular-1.
MX2010009195A (es) Rnas ultrapequeños como antagonistas del receptor tipo toll-3.
WO2010017154A3 (en) Modulation of toll-like receptor 3 expression by antisense oligonucleotides
WO2007137156A8 (en) Rnai modulation of aha and therapeutic uses thereof
WO2008036638A3 (en) Rnai modulation of scap and therapeutic uses thereof
MX347014B (es) Composición para administración de fármaco biodegradable.
WO2011116152A3 (en) Delivery of agents using interfering nanoparticles
MX2008008278A (es) Agonistas sinteticos novedosos de receptores tipo toll que contienen modificaciones de dinucleotido cg.
ATE472940T1 (de) Komprimierter kaugummi und verfahren zu seiner herstellung

Legal Events

Date Code Title Description
FG Grant or registration